Cargando…
Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19
IMPORTANCE: Multiple cases of autoimmune and autoinflammatory diseases after COVID-19 have been reported. However, their incidences and risks have rarely been quantified. OBJECTIVE: To investigate the incidences and risks of autoimmune and autoinflammatory connective tissue disorders after COVID-19....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559181/ https://www.ncbi.nlm.nih.gov/pubmed/37801317 http://dx.doi.org/10.1001/jamanetworkopen.2023.36120 |
_version_ | 1785117442252472320 |
---|---|
author | Lim, Sung Ha Ju, Hyun Jeong Han, Ju Hee Lee, Ji Hae Lee, Won-Soo Bae, Jung Min Lee, Solam |
author_facet | Lim, Sung Ha Ju, Hyun Jeong Han, Ju Hee Lee, Ji Hae Lee, Won-Soo Bae, Jung Min Lee, Solam |
author_sort | Lim, Sung Ha |
collection | PubMed |
description | IMPORTANCE: Multiple cases of autoimmune and autoinflammatory diseases after COVID-19 have been reported. However, their incidences and risks have rarely been quantified. OBJECTIVE: To investigate the incidences and risks of autoimmune and autoinflammatory connective tissue disorders after COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective population-based study conducted between October 8, 2020, and December 31, 2021, that used nationwide data from the Korea Disease Control and Prevention Agency COVID-19 National Health Insurance Service cohort and included individuals who received a diagnosis of COVID-19 via polymerase chain reaction testing and a control group with no evidence of COVID-19 identified from National Health Insurance Service of Korea cohort. Data analysis was conducted from September 2022 to August 2023. EXPOSURES: Receipt of diagnosis of COVID-19. MAIN OUTCOMES AND MEASURES: The primary outcomes were the incidence and risk of autoimmune and autoinflammatory connective tissue disorders following COVID-19. A total of 32 covariates, including demographics, socioeconomic statuses, lifestyle factors, and comorbidity profiles, were balanced through inverse probability weighting. The incidences and risks of autoimmune and autoinflammatory connective tissue disorders were compared between the groups using multivariable Cox proportional hazard analyses. RESULTS: A total of 354 527 individuals with COVID-19 (mean [SD] age, 52.24 [15.55] years; 179 041 women [50.50%]) and 6 134 940 controls (mean [SD] age, 52.05 [15.63] years; 3 074 573 women [50.12%]) were included. The risks of alopecia areata (adjusted hazard ratio [aHR], 1.12; 95% CI, 1.05-1.19), alopecia totalis (aHR, 1.74; 95% CI, 1.39-2.17), antineutrophil cytoplasmic antibody–associated vasculitis (aHR, 2.76; 95% CI, 1.64-4.65), Crohn disease (aHR, 1.68; 95% CI, 1.31-2.15), and sarcoidosis (aHR, 1.59; 95% CI, 1.00-2.52) were higher in the COVID-19 group. The risks of alopecia totalis, psoriasis, vitiligo, vasculitis, Crohn disease, ulcerative colitis, rheumatoid arthritis, adult-onset Still disease, Sjögren syndrome, ankylosing spondylitis, and sarcoidosis were associated with the severity of COVID-19. CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, COVID-19 was associated with a substantial risk for autoimmune and autoinflammatory connective tissue disorders, indicating that long-term management of patients with COVID-19 should include evaluation for such disorders. |
format | Online Article Text |
id | pubmed-10559181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-105591812023-10-08 Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19 Lim, Sung Ha Ju, Hyun Jeong Han, Ju Hee Lee, Ji Hae Lee, Won-Soo Bae, Jung Min Lee, Solam JAMA Netw Open Original Investigation IMPORTANCE: Multiple cases of autoimmune and autoinflammatory diseases after COVID-19 have been reported. However, their incidences and risks have rarely been quantified. OBJECTIVE: To investigate the incidences and risks of autoimmune and autoinflammatory connective tissue disorders after COVID-19. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective population-based study conducted between October 8, 2020, and December 31, 2021, that used nationwide data from the Korea Disease Control and Prevention Agency COVID-19 National Health Insurance Service cohort and included individuals who received a diagnosis of COVID-19 via polymerase chain reaction testing and a control group with no evidence of COVID-19 identified from National Health Insurance Service of Korea cohort. Data analysis was conducted from September 2022 to August 2023. EXPOSURES: Receipt of diagnosis of COVID-19. MAIN OUTCOMES AND MEASURES: The primary outcomes were the incidence and risk of autoimmune and autoinflammatory connective tissue disorders following COVID-19. A total of 32 covariates, including demographics, socioeconomic statuses, lifestyle factors, and comorbidity profiles, were balanced through inverse probability weighting. The incidences and risks of autoimmune and autoinflammatory connective tissue disorders were compared between the groups using multivariable Cox proportional hazard analyses. RESULTS: A total of 354 527 individuals with COVID-19 (mean [SD] age, 52.24 [15.55] years; 179 041 women [50.50%]) and 6 134 940 controls (mean [SD] age, 52.05 [15.63] years; 3 074 573 women [50.12%]) were included. The risks of alopecia areata (adjusted hazard ratio [aHR], 1.12; 95% CI, 1.05-1.19), alopecia totalis (aHR, 1.74; 95% CI, 1.39-2.17), antineutrophil cytoplasmic antibody–associated vasculitis (aHR, 2.76; 95% CI, 1.64-4.65), Crohn disease (aHR, 1.68; 95% CI, 1.31-2.15), and sarcoidosis (aHR, 1.59; 95% CI, 1.00-2.52) were higher in the COVID-19 group. The risks of alopecia totalis, psoriasis, vitiligo, vasculitis, Crohn disease, ulcerative colitis, rheumatoid arthritis, adult-onset Still disease, Sjögren syndrome, ankylosing spondylitis, and sarcoidosis were associated with the severity of COVID-19. CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, COVID-19 was associated with a substantial risk for autoimmune and autoinflammatory connective tissue disorders, indicating that long-term management of patients with COVID-19 should include evaluation for such disorders. American Medical Association 2023-10-06 /pmc/articles/PMC10559181/ /pubmed/37801317 http://dx.doi.org/10.1001/jamanetworkopen.2023.36120 Text en Copyright 2023 Lim SH et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License. |
spellingShingle | Original Investigation Lim, Sung Ha Ju, Hyun Jeong Han, Ju Hee Lee, Ji Hae Lee, Won-Soo Bae, Jung Min Lee, Solam Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19 |
title | Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19 |
title_full | Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19 |
title_fullStr | Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19 |
title_full_unstemmed | Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19 |
title_short | Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19 |
title_sort | autoimmune and autoinflammatory connective tissue disorders following covid-19 |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559181/ https://www.ncbi.nlm.nih.gov/pubmed/37801317 http://dx.doi.org/10.1001/jamanetworkopen.2023.36120 |
work_keys_str_mv | AT limsungha autoimmuneandautoinflammatoryconnectivetissuedisordersfollowingcovid19 AT juhyunjeong autoimmuneandautoinflammatoryconnectivetissuedisordersfollowingcovid19 AT hanjuhee autoimmuneandautoinflammatoryconnectivetissuedisordersfollowingcovid19 AT leejihae autoimmuneandautoinflammatoryconnectivetissuedisordersfollowingcovid19 AT leewonsoo autoimmuneandautoinflammatoryconnectivetissuedisordersfollowingcovid19 AT baejungmin autoimmuneandautoinflammatoryconnectivetissuedisordersfollowingcovid19 AT leesolam autoimmuneandautoinflammatoryconnectivetissuedisordersfollowingcovid19 |